LQDA — Liquidia
Liquidia (LQDA) — 2–3yr sleeve. YUTREPIA (inhaled treprostinil) is an approved dry-powder therapy for pulmonary arterial hypertension (PAH), with preliminary Q3 2026 net product sales of $222.7 million. The framework’s thesis rests on converting commercial launch momentum into durable revenue following the October settlement with United Therapeutics, which resolved outstanding litigation and preserved YUTREPIA commercialization for PAH.
Competitive context: United Therapeutics’ TYVASO franchise remains an established competitor, while Liquidia has stopped promoting YUTREPIA for PH-ILD and requested removal of that indication from its label. Sleeve assignment reflects an approved, scaling product and reduced litigation uncertainty, but not yet proven financial durability.
Named risk: $380.7 million in net settlement obligations, the loss of PH-ILD commercialization rights, and continuing competition could constrain long-duration compounding.
The BioCompound is a research publication. Nothing here constitutes investment advice.